Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec 7;15(12):1694-1695.
doi: 10.2215/CJN.16351020. Epub 2020 Nov 19.

Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?

Sophia Zoungas  1 , Kevan R Polkinghorne  2
Affiliations
Editorial

Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?

Sophia Zoungas et al. Clin J Am Soc Nephrol. .
No abstract available

Keywords: diabetes mellitus; kidney disease; sodium-glucose transporter 2 inhibitors.

PubMed Disclaimer

Comment on

References

    1. Deloitte Access Economics: Two of a KinD (Kidney in Diabetes): The Burden of Diabetic Kidney Disease and the Cost Effectiveness of Screening People with Type 2 Diabetes for Chronic Kidney Disease, Melbourne, Australia, Kidney Health Australia, 2011
    1. Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, Zoungas S, Cass A, Patel A, Marre M, Mancia G, Mogensen CE, Poulter N, Chalmers J; ADVANCE Collaborative Group: Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 60: 770–778, 2012 - PubMed
    1. de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, Sadusky T, Tandon N, Tuttle KR, Wanner C, Wilkens KG, Zoungas S, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli M, Cheung M, Earley A, Rossing P: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int 98: 839–848, 2020 - PubMed
    1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 - PubMed
    1. Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V: Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol 15: 1705–1714, 2020 - PMC - PubMed

MeSH terms

Substances